OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07

Submission of Matters to a Vote of Security Holders.

Ocular Therapeutix held its Annual Meeting of Stockholders on June14, 2018. The following is a summary of the matters voted on at that meeting.

(a)

Ocular Therapeutix’s stockholders elected Antony Mattessich, W. James O’Shea and Charles Warden as ClassI directors to serve until the 2021 Annual Meeting of Stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such ClassI directors were as follows:

Name

VotesFor

Votes Withheld

Broker Non-Votes

Antony Mattessich

15,588,755

3,217,038

14,553,989

W. James O’Shea

14,447,012

4,358,781

14,553,989

Charles Warden

14,949,006

3,856,787

14,553,989

(b)

Ocular Therapeutix’s stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December31, 2018. The result of the stockholders’ vote with respect to such ratification were as follows:

For

Against

Abstain

BrokerNon-Votes

32,785,789

286,003

287,990


About OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL)

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug. The OTX-TP product candidate incorporates the prostaglandin analog travoprost as an active pharmaceutical ingredient in its punctum plug.